Haichang Biotech
海昶生物
Haichang Biotech is a Chinese nucleic-acid drug delivery and complex formulation company, described in 2025 coverage as a domestic leader in those two areas . It develops innovative therapeutics built on lipid-nanoparticle (LNP) delivery technology—its HC016 lipid-complex injection, a TLR9 agonist, won simultaneous IND clearance in China and the US in early 2025 . The firm closed a nearly 500 million yuan Series C round in mid-2025 led by SDIC (Guangdong) Technology Achievement Transformation Venture Capital Fund, with Gaorong Capital—an earlier backer from its 2021 Series B—also participating . The proceeds are earmarked for advancing its nucleic-acid drug pipeline and new formulation work .
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
Haichang Biotech Closes Nearly 500 Million Yuan Series C Round to Accelerate Development of Innovative Nucleic Acid Drugs and Complex Injectables
Focused on the R&D and industrial application of drug delivery system technologies.
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
